BRPI0510159A - derivados de imidazol como inibidores de tafia - Google Patents

derivados de imidazol como inibidores de tafia

Info

Publication number
BRPI0510159A
BRPI0510159A BRPI0510159-0A BRPI0510159A BRPI0510159A BR PI0510159 A BRPI0510159 A BR PI0510159A BR PI0510159 A BRPI0510159 A BR PI0510159A BR PI0510159 A BRPI0510159 A BR PI0510159A
Authority
BR
Brazil
Prior art keywords
imidazole derivatives
tafia inhibitors
inhibitors
compounds
formula
Prior art date
Application number
BRPI0510159-0A
Other languages
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Andreas Lindenschmidt
Sven Gruenenberg
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510159(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0510159A publication Critical patent/BRPI0510159A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE IMIDAZOL COMO INIBIDORES DE TAFIA. A presente invenção refere-se a compostos de Fórmula que são inibidores de fibrinólise ativável por trombina ativada. Os compostos de Fórmula I são apropriados para a preparação de medicamentos para a prevenção e tratamento de doenças que acompanham tromboses, embolias, hipercoagulabilidade ou modificações fibróticas.
BRPI0510159-0A 2004-04-22 2005-04-07 derivados de imidazol como inibidores de tafia BRPI0510159A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (1)

Publication Number Publication Date
BRPI0510159A true BRPI0510159A (pt) 2007-10-02

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510159-0A BRPI0510159A (pt) 2004-04-22 2005-04-07 derivados de imidazol como inibidores de tafia

Country Status (35)

Country Link
EP (2) EP1864979B1 (pt)
JP (1) JP4939401B2 (pt)
KR (1) KR101162047B1 (pt)
CN (1) CN100572376C (pt)
AR (1) AR053302A1 (pt)
AT (2) ATE386737T1 (pt)
AU (1) AU2005238144B2 (pt)
BR (1) BRPI0510159A (pt)
CA (1) CA2563401C (pt)
CR (1) CR8650A (pt)
CY (1) CY1108087T1 (pt)
DE (2) DE102004020186A1 (pt)
DK (1) DK1740569T3 (pt)
EC (1) ECSP066941A (pt)
ES (1) ES2299026T3 (pt)
HK (1) HK1101823A1 (pt)
HR (1) HRP20080099T3 (pt)
IL (1) IL178672A (pt)
MA (1) MA28543B1 (pt)
MY (1) MY140903A (pt)
NI (1) NI200600217A (pt)
NO (1) NO20065320L (pt)
NZ (1) NZ550757A (pt)
PE (1) PE20060172A1 (pt)
PL (1) PL1740569T3 (pt)
PT (1) PT1740569E (pt)
RS (1) RS50553B (pt)
RU (1) RU2375356C2 (pt)
SI (1) SI1740569T1 (pt)
TN (1) TNSN06341A1 (pt)
TW (1) TWI359016B (pt)
UA (1) UA87306C2 (pt)
UY (1) UY28868A1 (pt)
WO (1) WO2005105781A1 (pt)
ZA (1) ZA200607668B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090087044A (ko) * 2006-12-06 2009-08-14 사노피-아벤티스 ＴＡＦＩａ 억제제로서의 요소 및 설파미드 유도체
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP2010518161A (ja) * 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
JP5531011B2 (ja) * 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
KR20120016651A (ko) 2009-05-15 2012-02-24 사노피 Ｔａｆｉａ의 억제제로서 유용한 화합물의 제조방법
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
RU2572814C2 (ru) 2010-03-18 2016-01-20 Дайити Санкио Компани, Лимитед ЦИКЛОАЛКИЛ-ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ ИМИДАЗОЛА, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ TAFIa
AU2011328263A1 (en) 2010-11-11 2013-05-30 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US9145385B2 (en) 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (de) 2011-11-25 2013-05-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
WO2017170460A1 (ja) 2016-03-29 2017-10-05 第一三共株式会社 炎症性腸疾患治療剤
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
BR0307033A (pt) 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas

Also Published As

Publication number Publication date
KR101162047B1 (ko) 2012-07-04
ES2299026T3 (es) 2008-05-16
JP2007533672A (ja) 2007-11-22
KR20070007346A (ko) 2007-01-15
TNSN06341A1 (en) 2008-02-22
RU2375356C2 (ru) 2009-12-10
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
HRP20080099T3 (en) 2008-03-31
PL1740569T3 (pl) 2008-07-31
UY28868A1 (es) 2005-11-30
PE20060172A1 (es) 2006-03-31
SI1740569T1 (sl) 2008-06-30
IL178672A0 (en) 2007-02-11
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
CY1108087T1 (el) 2014-02-12
RU2006141246A (ru) 2008-06-10
IL178672A (en) 2011-08-31
WO2005105781A1 (de) 2005-11-10
RS50553B (sr) 2010-05-07
NO20065320L (no) 2007-01-12
CR8650A (es) 2007-12-04
TWI359016B (en) 2012-03-01
HK1101823A1 (en) 2007-10-26
PT1740569E (pt) 2008-03-31
EP1740569B1 (de) 2008-02-20
ATE523505T1 (de) 2011-09-15
ZA200607668B (en) 2008-03-26
TW200602325A (en) 2006-01-16
DK1740569T3 (da) 2008-06-02
NI200600217A (es) 2008-06-17
CA2563401C (en) 2012-08-07
DE502005002927D1 (de) 2008-04-03
ECSP066941A (es) 2006-12-20
NZ550757A (en) 2010-06-25
EP1740569A1 (de) 2007-01-10
MA28543B1 (fr) 2007-04-03
AR053302A1 (es) 2007-05-02
EP1864979A1 (de) 2007-12-12
AU2005238144B2 (en) 2010-08-26
UA87306C2 (en) 2009-07-10
MY140903A (en) 2010-01-29
DE102004020186A1 (de) 2005-11-17
ATE386737T1 (de) 2008-03-15
CA2563401A1 (en) 2005-11-10
EP1864979B1 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
BRPI0510159A (pt) derivados de imidazol como inibidores de tafia
BR112022007163A2 (pt) Heterociclos bicíclicos como inibidores de fgfr
BR112015022462A2 (pt) inibidores de ido
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
BR112013017635A2 (pt) inibidores de cyp11b, cyp17 e/ou cyp21
DOP2010000363A (es) Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia
EA201170832A1 (ru) Пуриновые соединения
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
DOP2010000101A (es) Nuevos inhibidores de epoxido hidrolasas soluble (seh) y procedimientos
BR112015019412A2 (pt) inibidores de bace1
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
MX2009005516A (es) Derivados de urea y de sulfamida en calidad de inhibidores de tafia.
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
WO2009040314A3 (de) Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2
MX2011013869A (es) Agentes antihelminticos y su uso.
GEP20135998B (en) Heterocyclic sulfonamide derivatives
TW200735880A (en) Medicinal compositions for preventing or treating heart failure
BRPI0601390B8 (pt) uso de inibidores de proteases de bauhinia bauhinioides e/ou enterolobium contortisiliquum
BR112018016515A2 (pt) derivados de tetrazol como inibidores de citocromo p450

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]